Slingshot members are tracking this event:
OncoSec's (ONCS) ImmunoPulse Il-12 Granted Fast Track Status by FDA for Metastatic Melanoma Following Progression on Merck's (MRK) KEYTRUDA or Bristol-Myers Squibb's (BMY) Opdivo
Slingshot Insights Explained
Feb 27, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Immunopulse Il-12, Fast Track Status, Metastatic Melanoma, Keytruda, Opdivo